TCGA-49-4512-01A-21R-1858-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- ANGIOGENESIS+0.380
- COAGULATION+0.370
- KRAS_SIGNALING_DN+0.320
- MYOGENESIS+0.320
- PANCREAS_BETA_CELLS+0.310
- HEDGEHOG_SIGNALING+0.190
- KRAS_SIGNALING_UP+0.190
- APICAL_SURFACE+0.170
- APICAL_JUNCTION+0.130
Top 10 suppressed
- MYC_TARGETS_V1-0.660
- E2F_TARGETS-0.610
- G2M_CHECKPOINT-0.600
- MTORC1_SIGNALING-0.540
- MYC_TARGETS_V2-0.530
- UNFOLDED_PROTEIN_RESPONSE-0.530
- PROTEIN_SECRETION-0.520
- MITOTIC_SPINDLE-0.510
- PI3K_AKT_MTOR_SIGNALING-0.470
- DNA_REPAIR-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-ZF-A9R9-01A-11R-A38B-07 | — | — | 0.943 |
| 2 | SRR1440962 | GTEX | — | 0.942 |
| 3 | SRR1487825 | GTEX | — | 0.936 |
| 4 | BS_MQCKXD60 | Glial-neuronal tumor NOS | — | 0.931 |
| 5 | SRR1394713 | GTEX | — | 0.931 |
| 6 | SRR12202400 | — | — | 0.929 |
| 7 | SRR1378155 | GTEX | — | 0.929 |
| 8 | SRR1382956 | GTEX | — | 0.926 |
| 9 | SRR1316624 | GTEX | — | 0.924 |
| 10 | SRR1340301 | GTEX | — | 0.924 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.020 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |